Back to top
more

PerkinElmer, Inc. (PKI)

(Delayed Data from NYSE)

$96.59 USD

96.59
692,880

+1.71 (1.80%)

Updated May 3, 2019 04:03 PM ET

After-Market: $96.59 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

LabCorp (LH) Q4 Earnings Beat Estimates, '18 View Promising

LabCorp's (LH) Covance Drug Development of late begins to gain traction from Chiltern acquisition, strong organic growth and a favorable foreign currency translation.

    AmerisourceBergen (ABC) Beats on Q1 Earnings, FY18 View Up

    Strong Growth in Pharmaceutical Distribution Segment and World Courier business drove AmerisourceBergen (ABC) in Q1.

      Phibro Animal (PAHC) Beats on Q2 Earnings, Raises Guidance

      Phibro (PAHC) witnesses year-over-year improvement across all segments in Q2.

        Align Technology Banks on Global Growth, Competition Rife

        We are encouraged by Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally, particularly in Asia Pacific.

          Becton, Dickinson (BDX) Beats on Q1 Earnings, Guidance Solid

          Strong growth in BD Medical and BD Life sciences segments drove Becton, Dickinson's (BD) top line in Q1.

            Genomic Health (GHDX) Oncotype DX GPS Test Results Positive

            Genomic Health's (GHDX) efforts to improve its prostate cancer business are encouraging.

              IDEXX Laboratories Strong on CAG Business Amid Currency Woes

              IDEXX's (IDXX) innovation-based global strategy is leading to growth at CAG Diagnostics.

                Cardiovascular Systems' Micro Crown Now Available in Japan

                Cardiovascular Systems (CSII) is positioned to gain from favorable trend in the CAD market.

                  athenahealth (ATHN) Tops Earnings & Revenue Estimates in Q4

                  Strong growth in Business and Services segment drove athenahealth's (ATHN) top line in Q4.

                    Hill-Rom (HRC) Trades on Product Innovation, Competition Rife

                    Hill-Rom (HRC) focuses on product innovation, the latest launch being Connex Cardio ECG.

                      Integra LifeSciences Global Prospects Solid, Competition Rife

                      Integra LifeSciences (IART) witnesses strong global sales within specialty surgical driven by strength in door repair and tissue ablation franchises in Asia Pacific and Europe.

                        Omnicell (OMCL) Earnings Beat, Revenues Miss Estimates in Q4

                        Omnicell's (OMCL) year-over-year growth at both the segments in Q4 is encouraging.

                          ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3

                          ABIOMED (ABMD) rides high on record revenues from Impella in third-quarter fiscal 2018. The company is also well poised with new accomplishments.

                            Pacific Biosciences (PACB) Q4 Loss Narrows, Consumables Up

                            Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.

                              Edwards Lifesciences (EW) Beats on Q4 Earnings and Revenues

                              Edwards Lifesciences (EW) gains from strength in THVT on continued therapy adoption across all geographies in Q4.

                                Quest Diagnostics (DGX) Tops Q4 Earnings, 2018 View Strong

                                Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.

                                  Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top

                                  In Q4, Boston Scientific (BSX) registers balanced growth across all business lines and geographies.

                                    Conmed (CNMD) Beats Earnings and Revenue Estimates in Q4

                                    Conmed (CNMD) benefits from impressive general surgery performance and enhanced innovation in Q4.

                                      McKesson (MCK) Beats on Q3 Earnings & Revenues, Ups '18 View

                                      Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.

                                        Baxter (BAX) Beats on Q4 Earnings & Revenues, '18 View Solid

                                        Strong performance in the Hospital Products and Renal Products segments drives Baxter (BAX) in Q4.

                                          IDEXX Laboratories (IDXX) Beats on Q4 Earnings and Revenues

                                          IDEXX (IDXX) rides high on strength in CAG business in Q4. A raised guidance buoys optimism.

                                            QIAGEN (QGEN) Beats on Q4 Earnings and Revenues, Issues View

                                            QIAGEN's (QGEN) year-over-year growth in Q4 revenues is encouraging. Expansion in operating margin buoys optimism.

                                              Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines

                                              Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.

                                                Stryker (SYK) Beats Earnings and Revenue Estimates in Q4

                                                Stryker's (SYK) Q4 results benefit from Mako product platform and higher organic sales.

                                                  Illumina (ILMN) Tops Q4 Earnings & Revenues, Issues Guidance

                                                  Illumina (ILMN) gains from strength in sequencing consumables and instruments as well as microarray portfolios in Q4.